Previous 10 | Next 10 |
2024-02-20 21:29:31 ET Summary Tweedy Browne's 13F portfolio value increased from $1.87B to $2.05B this quarter. The largest position in the portfolio is Berkshire Hathaway at ~21%. Stake increases include FMC Corporation, U-Haul Holding, and Sealed Air, while stake decreases ...
2024-02-20 11:18:12 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis receives FDA orphan drug status for familial chylomicronemia drug Ionis-AstraZeneca amyloid cardiomyopathy candidate gets FDA fast track designation ...
2024-02-15 07:20:49 ET Read the full article on Seeking Alpha For further details see: Ionis receives FDA orphan drug status for familial chylomicronemia drug
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome PR Newswire CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administrat...
2024-02-14 21:40:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...
2024-02-08 08:35:27 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis angioedema drug shows positive results in Phase 3 trial FDA approves AstraZeneca, Ionis drug for ATTRv-PN Seeking Alpha’s Quant Rating on Io...
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy PR Newswire CARLSBAD, Calif. , Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and D...
Ionis to hold fourth quarter and full year 2023 financial results webcast PR Newswire Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq:...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
2024-01-22 14:00:02 ET William Blair analyst issues OUTPERFORM recommendation for IONS on January 22, 2024 02:35PM ET. The previous analyst recommendation was Outperform. IONS was trading at $51.455 at issue of the analyst recommendation. The overall analyst consensus : ...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...